EWTX News and Press, Edgewise Therapeutics Inc. From 09/07/22

- Initiation of LYNX Phase 2 clinical trial in individuals with DMD expected in Q4 2022 - Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle ...

Edgewise Therapeutics press release ( NASDAQ: EWTX ): Q2 GAAP EPS of -$0.32 beats by $0.02 . Cash, cash equivalents and marketable securities of $248.4 million as of June 30, 2022 For further details see: Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.0...

– Announced positive 2-month interim results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (BMD) – – Initiated Phase 2 trial in BMD; Expect to start Phase 2 trial in Duchenne muscular dystrophy (DMD) in 2022 –...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in a panel ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers six blue-chip stocks to sell now. These stocks are severely overvalued or are likely to move down soon due to the coming recession or a slump in demand. The point is analysts’ forecasts are like...

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506...

– EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – ...

- Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Ed...

Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The number of positions decreased from 107 to 56. Viking Global increased Amazon.com, Fortive, and International Flavors & Fragrances while dropping Humana, Coupa Software, and Twilio. The top thre...

The following slide deck was published by Edgewise Therapeutics, Inc. in conjunction with this event. For further details see: Edgewise Therapeutics (EWTX) Investor Presentation - Slideshow